- cafead Jul 16, 2024 at 11:22: PM
via US-based biotechnology company Cytonics has started a Phase I clinical trial of a new therapeutic for osteoarthritis of the knee.
The first-in-human study aims to evaluate CYT-108, a recombinant protein designed to inhibit proteases that degrade cartilage in arthritic joints.
article source
The first-in-human study aims to evaluate CYT-108, a recombinant protein designed to inhibit proteases that degrade cartilage in arthritic joints.
article source